JPH06505396A - 可溶性ｃｄ２８タンパク質およびそれを用いる治療方法 - Google Patents
可溶性ｃｄ２８タンパク質およびそれを用いる治療方法Info
- Publication number
- JPH06505396A JPH06505396A JP4508778A JP50877892A JPH06505396A JP H06505396 A JPH06505396 A JP H06505396A JP 4508778 A JP4508778 A JP 4508778A JP 50877892 A JP50877892 A JP 50877892A JP H06505396 A JPH06505396 A JP H06505396A
- Authority
- JP
- Japan
- Prior art keywords
- soluble
- compound
- protein
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 title claims description 56
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 title claims description 55
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 239000013604 expression vector Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 239000000539 dimer Substances 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 238000010253 intravenous injection Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 239000012634 fragment Substances 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101150100936 CD28 gene Proteins 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- BYJQAPYDPPKJGH-UHFFFAOYSA-N 3-(2-carboxyethyl)-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2C(CCC(=O)O)=C(C(O)=O)NC2=C1 BYJQAPYDPPKJGH-UHFFFAOYSA-N 0.000 description 1
- 206010067272 Anal erosion Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102000038504 B7-1 Antigen Human genes 0.000 description 1
- 108010035053 B7-1 Antigen Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102000010910 CD28 Antigens Human genes 0.000 description 1
- 108010062433 CD28 Antigens Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000620894 Homo sapiens Lysophosphatidic acid phosphatase type 6 Proteins 0.000 description 1
- 101001135804 Homo sapiens Protein tyrosine phosphatase receptor type C-associated protein Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102100036937 Protein tyrosine phosphatase receptor type C-associated protein Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 101150027332 cit gene Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- -1 phosphatidylinositol glycan Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66680991A | 1991-03-08 | 1991-03-08 | |
| US666,809 | 1991-03-08 | ||
| PCT/US1992/001867 WO1992015671A1 (en) | 1991-03-08 | 1992-03-09 | Soluble cd28 proteins and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06505396A true JPH06505396A (ja) | 1994-06-23 |
Family
ID=24675579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4508778A Pending JPH06505396A (ja) | 1991-03-08 | 1992-03-09 | 可溶性ｃｄ２８タンパク質およびそれを用いる治療方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0575537A1 (enrdf_load_stackoverflow) |
| JP (1) | JPH06505396A (enrdf_load_stackoverflow) |
| WO (1) | WO1992015671A1 (enrdf_load_stackoverflow) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6642390A (en) * | 1989-10-27 | 1991-05-31 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US7070776B1 (en) | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| WO1992000092A1 (en) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
| US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| AU7638894A (en) * | 1993-09-03 | 1995-03-22 | Miyuki Azuma | B70(b7-2):ctla-4 bonding protein |
| EP0749323B1 (en) | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
| HUP9801629A3 (en) * | 1995-02-09 | 2000-10-30 | Icn Pharmaceuticals Inc Costa | Methods and compositions for regulation of cd28 expression |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US7078512B2 (en) | 1998-05-01 | 2006-07-18 | Schering-Plough Animal Health Corporation | Nucleic acid encoding feline CD86 |
| US7279168B2 (en) | 1998-05-01 | 2007-10-09 | Texas A & M University System | Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| US8535672B2 (en) | 2002-04-04 | 2013-09-17 | Yissum Research Development Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof |
| CA2614640A1 (en) | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| SG177907A1 (en) | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| ES2776698T3 (es) | 2012-12-20 | 2020-07-31 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| AU2019218729A1 (en) | 2018-02-06 | 2020-08-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992000092A1 (en) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand for cd28 receptor on b cells and methods |
-
1992
- 1992-03-09 EP EP92909064A patent/EP0575537A1/en not_active Withdrawn
- 1992-03-09 JP JP4508778A patent/JPH06505396A/ja active Pending
- 1992-03-09 WO PCT/US1992/001867 patent/WO1992015671A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0575537A1 (en) | 1993-12-29 |
| EP0575537A4 (enrdf_load_stackoverflow) | 1994-04-06 |
| WO1992015671A1 (en) | 1992-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06505396A (ja) | 可溶性ｃｄ２８タンパク質およびそれを用いる治療方法 | |
| US7638281B2 (en) | Polypeptide, cDNA encoding the same and use of them | |
| RU2642302C1 (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| MXPA04004489A (es) | Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas. | |
| KR19990063825A (ko) | 절단된자신경교세포주-유래 신경영양성 인 | |
| EP0990703B1 (en) | Novel polypeptide, dna encoding the same and use thereof | |
| JP2000500336A (ja) | Ｆａｓリガンド融合タンパク質 | |
| MXPA06010655A (es) | Citocina inmunosupresora. | |
| CA2374681C (en) | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection | |
| KR100692226B1 (ko) | 신규 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및 그 용도 | |
| EP1090992A1 (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
| WO1999058668A1 (fr) | Nouveaux polypeptides, adn complementaires les codant et utilisation de ces polypeptides | |
| KR20010072289A (ko) | 신규한 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ및 그 용도 | |
| US5807714A (en) | Method of production of antigen-specific glycosylation inhibiting factor | |
| EP1022336A1 (en) | POLYPEPTIDE, cDNA ENCODING THE SAME, AND USE OF THEM | |
| JPS6229981A (ja) | サルコフア−ガ・レクチンの構造遺伝子 | |
| US20050003488A1 (en) | Polypeptide, cDNA encoding the same, and use of them | |
| US20040241804A1 (en) | Novel polypeptide, a cDNA encoding the same, and use of it | |
| WO2024006576A1 (en) | Mhc class ii protein constructs | |
| JPH1014581A (ja) | ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片 | |
| AU1204799A (en) | Viral encoded semaphorin protein receptor dna and polypeptides |